Shilpa Medicare's subsidiary, Shilpa Biocare, acquired a 30.4% stake in Spain's Gate2Brain for €7 million. The deal aims to advance a novel oncology asset targeting pediatric brain cancers.
Shilpa Medicare Subsidiary Acquires Stake in Gate2Brain for €7 Million
Shilpa Biocare Pvt Ltd, a wholly-owned subsidiary of Shilpa Medicare Limited, has acquired a 30.4% equity stake in Barcelona-based biotechnology firm Gate2Brain S.L. for a total consideration of €7 million. The transaction is not classified as a related party transaction. ## What just happened Shilpa Biocare will serve as the dedicated manufacturing and regulatory partner for Gate2Brain's lead program, G2B-002. This asset is a peptide-shuttle oncology drug designed to deliver therapeutics across the blood-brain barrier and has received Orphan Drug Designation from the U.S. FDA and EMA. ## Why this matters This strategic investment allows Shilpa Medicare to expand into specialized Central Nervous System (CNS) delivery platforms. The partnership is a long-term play, aiming to develop treatments for rare and aggressive pediatric brain cancers like DIPG and pediatric glioblastoma. ## The backstory This marks the fourth such investment for Shilpa Medicare, indicating a strategic focus on acquiring differentiated innovation and building a portfolio of high-potential therapeutic assets. The deal structures investment across cash, equity for services, and project development. ## What changes now Shilpa Biocare will manage the Chemistry, Manufacturing, and Controls (CMC) for G2B-002. The company anticipates clinical batches by next year, with first-in-human trials expected by FY28. This investment is a strategic, long-term venture. ## Risks to watch The venture is in the pre-clinical stage, carrying inherent developmental and regulatory risks typical of the biotechnology sector. Returns on this investment are expected to be long-term. ## Peer comparison Gate2Brain's lead program, G2B-002, targets significant market opportunities. Third-party data estimates the Glioblastoma Treatment market at USD 3.01 billion by 2025, the Pediatric Brain Tumor market at USD 1.55 billion by 2024, and the DIPG market at USD 603.7 million by 2025. ## Context metrics (time-bound) The investment totals €7 million, comprising a €0.5 million cash infusion, €5.5 million in equity for services, and €1.0 million for project development. ## What to track next Investors should monitor the progress of clinical batch preparation, regulatory milestones for G2B-002, and the timeline for commencing human trials by FY28. Reader Takeaway: Expands CNS drug delivery footprint with a strategic, long-term investment in a promising oncology asset.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
